Global HIV Prevention Drug Set for $40 in Developing Nations, $28,000 in the US
Generic versions of lenacapavir, a twice-yearly injectable HIV-prevention drug, will be available in 120 low- and middle-income countries for $40 annually beginning in 2027. Unitaid and the Gates Foundation have partnered with Indian pharmaceutical companies to produce these affordable generic versions, which have shown to reduce the risk of HIV transmission by over 99.9 percent. This initiative expands access to the drug, currently priced at $28,000 per year in the United States, marking a significant step in global HIV prevention efforts. This will help with the efforts to end the HIV epidemic.
John Q. Hosedrinker